Guardant Health (NASDAQ:GH) Given Outperform Rating at Sanford C. Bernstein

Guardant Health (NASDAQ:GH)‘s stock had its “outperform” rating reissued by investment analysts at Sanford C. Bernstein in a research note issued on Friday,Benzinga reports. They currently have a $175.00 price target on the stock. Sanford C. Bernstein’s target price would suggest a potential upside of 22.43% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the company. BTIG Research set a $160.00 price target on Guardant Health and gave the company a “buy” rating in a research note on Wednesday, May 27th. TD Cowen reiterated a “buy” rating on shares of Guardant Health in a report on Thursday, May 21st. JPMorgan Chase & Co. increased their price objective on shares of Guardant Health from $130.00 to $135.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Evercore upgraded shares of Guardant Health from an “in-line” rating to an “outperform” rating and set a $160.00 target price for the company in a research note on Tuesday, June 2nd. Finally, Guggenheim downgraded shares of Guardant Health from a “buy” rating to a “buy” rating in a report on Thursday, May 28th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Guardant Health currently has an average rating of “Moderate Buy” and a consensus price target of $143.68.

Guardant Health Stock Up 4.4%

GH opened at $142.94 on Friday. Guardant Health has a 12-month low of $40.35 and a 12-month high of $145.84. The business has a 50 day moving average of $111.34 and a 200-day moving average of $103.70. The stock has a market cap of $18.95 billion, a price-to-earnings ratio of -42.17 and a beta of 1.61.

Insider Transactions at Guardant Health

In other Guardant Health news, Director Meghan V. Joyce sold 10,000 shares of the stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $126.98, for a total transaction of $1,269,800.00. Following the transaction, the director owned 11,183 shares in the company, valued at $1,420,017.34. This trade represents a 47.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John G. Saia sold 20,000 shares of Guardant Health stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $106.51, for a total value of $2,130,200.00. Following the sale, the insider directly owned 45,950 shares of the company’s stock, valued at $4,894,134.50. This represents a 30.33% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 452,513 shares of company stock worth $51,608,916. 5.60% of the stock is currently owned by company insiders.

Institutional Trading of Guardant Health

A number of institutional investors have recently bought and sold shares of the business. V Square Quantitative Management LLC acquired a new position in shares of Guardant Health during the 4th quarter worth approximately $27,000. Chesapeake Asset Management LLC bought a new position in shares of Guardant Health during the fourth quarter worth approximately $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Guardant Health in the fourth quarter valued at approximately $31,000. Elyxium Wealth LLC acquired a new stake in shares of Guardant Health in the fourth quarter valued at approximately $35,000. Finally, Parallel Advisors LLC boosted its stake in shares of Guardant Health by 164.7% in the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after buying an additional 219 shares during the period. Institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.